Immunotherapy has proven to be effective against many serious diseases. But to treat diseases in the brain, the antibodies must first get past the obstacle of the blood-brain barrier. In a new study, a research group at Uppsala University describes their development of a new antibody design that increases brain uptake of antibodies almost 100-fold.
Immunotherapy entails treatment with antibodies; it is the fastest growing field in pharmaceutical development. In recent years, immunotherapy has successfully been used to treat cancer and rheumatoid arthritis, and the results of clinical studies look very promising for several other diseases. Antibodies are unique in that they can be modified to strongly bind to almost any disease-causing protein. In other words, major potential exists for new antibody-based medicines.
The problem with immunotherapy for diseases affecting the brain is that the brain is protected by a very tight layer of cells, called the blood-brain barrier. The blood-brain barrier effectively prevents large molecules, such as antibodies, from passing from the bloodstream into the brain. It has therefore been difficult to use immunotherapy to treat Alzheimer’s and Parkinson’s disease, which affect the brain, as well as cancerous tumours in the brain.
It has been known for a long time that some large proteins are actively transported across the blood-brain barrier. These include a protein called transferrin, whose primary task is to bind to iron in the blood and then transport it to the brain. The research group behind this new study has taken advantage of this process and modified the antibodies they want to transport into the brain using components that bind to the transferrin receptor. Then, like a Trojan horse, the receptor transports antibodies into the brain. The number of modifications to and placement of the antibodies have proven to be important factors for making this process as effective as possible.
“We’ve placed them so that each antibody only binds with one modification at a time, despite being modified in two places. Our design thus doubles the chances of the antibody binding to the transferrin receptor compared with only one modification. We’ve successfully increased the amount of antibodies in the brain almost 100-fold, which is the largest uptake improvement that has ever been shown,” says Greta Hultqvist, researcher at the Department of Public Health and Caring Sciences at Uppsala University.
To try out the new format, researchers have used it on an antibody that binds to a protein involved in the course of Alzheimer’s disease. Without the modification, they could only detect very small quantities of antibody in the brain in a mouse model of Alzheimer’s disease, while they could detect high levels of the modified antibody in the same mice.
“From a long-term perspective, it’s likely that the new format can be used to effectively treat not only Alzheimer’s disease, but also other diseases affecting the brain,” says Dag Sehlin, researcher at the Department of Public Health and Caring Sciences at Uppsala University.
Receive an email update when we add a new IMMUN0THERAPY article.
The Latest on: Immunotherapy
via Google News
The Latest on: Immunotherapy
- Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapyon January 10, 2020 at 2:13 am
Here we perform TCRB sequencing, integration site analysis, and single-cell RNA sequencing (scRNA-seq) to profile CD8 + CAR-T cells from infusion products (IPs) and blood of patients undergoing CD19 ...
- Cancer Immunotherapy Market on eye to reach $117.11 Billion by 2022on January 9, 2020 at 8:11 pm
The Global Cancer Immunotherapy Marketwas valued at $45,471 million in 2015, and is projected to reach $117,114 million by 2022, growing at a CAGR of 14.5% from 2016 to 2022. The monoclonal antibodies ...
- Nano-sized copper compounds together with immunotherapy can kill cancer cellson January 9, 2020 at 12:14 pm
An interdisciplinary team of scientists from KU Leuven, the University of Bremen, the Leibniz Institute of Materials Engineering, and the University of Ioannina has succeeded in killing tumor cells in ...
- Cancer Immunotherapy Market 2020 Size, Share Metrics, Growth Trends and Forecast to 2026on January 9, 2020 at 1:27 am
New Jersey, United States, - Verified Market Research indicates that the Cancer Immunotherapy Market is expected to surge at a steady rate in the coming years, as economies flourish. The research ...
- Cancer death rate declines sharply, partly thanks to immunotherapyon January 8, 2020 at 6:45 pm
The U.S. cancer death rate has declined by the largest single-year amount on record, according to new statistics, improvement fueled in no small part by recent advances such as immunotherapy, the ...
- Lung cancer immunotherapy gets initial ‘no’ for NHS in Englandon January 8, 2020 at 7:17 am
A combination of immunotherapy and chemotherapy has been rejected by the National Institute for Health and Care Excellence (NICE) for some adults with small cell lung cancer. The combination treatment ...
- Melanoma Immunotherapy Enhanced by Targeting Treg Cell Control Proteinon January 8, 2020 at 5:19 am
“Our study shows that a PD-1 inhibitor can be used to treat tumors that currently do not respond to this therapy, when administered in mice lacking the Siah2 gene, thereby offering a means to expand ...
- Study reveals a new approach to enhancing response to immunotherapy in melanomaon January 7, 2020 at 2:01 am
The research, which offers a new avenue to pursue immunotherapy in cases where the treatment fails, was published today in Nature Communications. "While Siah2 is involved in control of activities that ...
- Frontline immunotherapy for NSCLC — the tale of the tailon January 6, 2020 at 3:20 am
The CHECKMATE-227 trial of nivolumab and ipilimumab presents a potential new frontline chemotherapy-sparing treatment option for patients with PD-L1-positive non-small-cell lung cancer and perhaps, in ...
via Bing News